Back to Search Start Over

Hepatobiliary involvement in systemic sclerosis and the cutaneous subsets: Characteristics and survival of patients from the Spanish RESCLE Registry

Authors :
Mari-Alfonso, B
Pilar Simeon-Aznar, Carmen
Guillen-Del Castillo, A
Rubio-Rivas, M
Trapiella-Martinez, L
Antonio Todoli-Parra, Jose
Rodriguez Carballeira, Monica
Marin-Ballve, A
Iniesta-Arandia, N
Colunga-Arguelles, D
Jesus Castillo-Palma, Maria
Saez-Comet, L
Victoria Egurbide-Arberas, Maria
Ortego-Centeno, N
Freire, M
Vargas Hitos, Jose Antonio
Chamorro, AJ
Belen Madronero-Vuelta, Ana
Perales-Fraile, I
Pla-Salas, X
Fernandez-De-La-Puebla, RA
Fonollosa-Pla, V
Tolosa-Vilella, C
RESCLE Investigators
Systemic Autoimmune Dis Study Grp
Source :
SEMINARS IN ARTHRITIS AND RHEUMATISM, r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe, instname
Publication Year :
2018
Publisher :
W B SAUNDERS CO-ELSEVIER INC, 2018.

Abstract

Objective: To assess the prevalence and causes of hepatobiliary involvement (HBI) in systemic sclerosis (SSc), to investigate the clinical characteristics and prognosis of SSc patients with HBI (SSc-HBI) and without HBI (SSc-non-HBI), and to compare both groups according to the cutaneous SSc subsets. Methods: In all, 1572 SSc patients were collected in the RESCLE registry up to January 2015, and all hepatobiliary disturbances were recorded. We investigated the HBI-related characteristics and survival from the entire SSc cohort and according to the following cutaneous subsets: diffuse cutaneous SSc (dcSSc), limited cutaneous SSc (lcSSc), and SSc sine scleroderma (ssSSc). Results: Out of 1572, 118 (7.5%) patients had HBI. Primary biliary cholangitis (PBC) was largely the main cause (n = 67, 4.3%), followed by autoimmune hepatitis (n = 19, 1.2%), and anti-mitochondrial negative PBC (n = 6, 0.4%). Other causes of HBI were as follows: secondary liver diseases (n = 11, 0.7%), SSc-related HBI (n = 7, 0.4%), nodular regenerative hyperplasia (n = 3, 0.2%), liver cirrhosis (n = 3, 0.2%), and HBI of unknown origin (n = 2, 0.1%). In multivariate analysis, HBI was independently associated to lesser risk of dcSSc (5.1% vs. 24.4%), and higher frequency of calcinosis (26% vs. 18%), left ventricular diastolic dysfunction (46% vs. 27%), sicca syndrome (51% vs. 29%), and anti-centromere antibodies (ACA, 73% vs. 44%). According to the cutaneous subsets, HBI was associated (1) in lcSSc, to longer time from SSc onset to diagnosis (10.8 +/- 12.5 vs. 7.2 +/- 9.3 years), sicca syndrome (54% vs. 33%), and ACA (80% vs. 56%); (2) in ssSSc, to sicca syndrome (44% vs. 19%), and (3) in dcSSc, no associations were found. HBI was the cause of death in 23% patients but the cumulative survival according to the presence or absence of HBI showed no differences. Conclusions: HBI prevalence in SSc is 7.5% and dcSSc is the least involved subset. PBC is the main cause of HBI. Patients with SSc-HBI exhibited specific clinical and immunologic profile. Survival is similar for SSc patients with HBI (C). 2017 Elsevier Inc. All rights reserved.

Details

ISSN :
00490172
Database :
OpenAIRE
Journal :
SEMINARS IN ARTHRITIS AND RHEUMATISM, r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe, instname
Accession number :
edsair.RECOLECTA.....64dc4817433c9334b42353b14475452c